tldrdailynews.com logo
Tag

Eli Lilly

All articles tagged with #eli lilly

Lilly bets $4B on infectious-disease push with three acquisitions
business8 hours ago

Lilly bets $4B on infectious-disease push with three acquisitions

Eli Lilly said it will buy Curevo, LimmaTech Biologics and The Vaccine Company for almost $4 billion in cash to expand infectious-disease R&D, sending its shares higher in premarket trading. Curevo develops a shingles vaccine, LimmaTech targets resistant bacterial pathogens including STIs, and The Vaccine Company advances in vivo nanoparticle delivery technologies for drugs, genes, and diagnostics. The move comes as Lilly relies on Zepbound and Mounjaro for strong revenue and introduces Foundayo to compete with Novo Nordisk in obesity treatments.

via CNBC|
#acquisitions#business#eli-lilly
Lilly’s triple-hormone retatrutide shows leading obesity trial results
business5 days ago

Lilly’s triple-hormone retatrutide shows leading obesity trial results

Phase 3 data show Lilly’s investigational triple-hormone drug retatrutide delivering up to 28.3% average weight loss over 80 weeks at the highest dose (vs. 2.2% placebo), with about 45% of patients achieving 30%+ loss and even greater reductions in those with BMI ≥35. A lower 4 mg dose yielded 19% weight loss with better tolerability. Common side effects were GI (nausea, diarrhea, constipation); no major cardiac or liver issues were observed. If results hold, Lilly could file for approval, potentially solidifying retatrutide as a top player in a booming obesity market, ahead of Novo Nordisk’s competing therapies.

via CNBC|
#business#eli-lilly#glp-1gipglucagon
Next-gen obesity drug race tightens as pivotal readouts loom
business7 days ago

Next-gen obesity drug race tightens as pivotal readouts loom

Pharma is racing to commercialize next-generation obesity drugs as pivotal readouts approach from Lilly, Viking Therapeutics, and Pfizer; Lilly’s retatrutide shows potentially stronger weight loss and knee-pain relief in Triumph-4, Viking is testing maintenance dosing for VK2735, and Pfizer’s PF’3944 posted encouraging phase 2b results for monthly maintenance injections, signaling a crowded path to a multi-billion GLP-1 market by 2030.

via Pharma Voice|
#business#eli-lilly#glp-1
Novo's Wegovy Pill Surges Ahead of Lilly's Foundayo in Early Rollout
business22 days ago

Novo's Wegovy Pill Surges Ahead of Lilly's Foundayo in Early Rollout

Novo Nordisk’s Wegovy oral pill has gained strong early momentum since its January launch, aided by aggressive marketing and a lower monthly price, while Lilly’s Foundayo is ramping up more slowly. Telehealth platforms report rapid uptake for Wegovy, and investors are watching first-quarter results and potential international expansion as the GLP-1 pill market expands beyond injections.

via CNBC|
#business#eli-lilly#foundayo
Lilly rides weight-loss drug wave to first-quarter profit surge
business26 days ago

Lilly rides weight-loss drug wave to first-quarter profit surge

Eli Lilly more than doubled its Q1 profits as demand for obesity and diabetes medications drove revenue higher, with Mounjaro sales at $8.7bn and Zepbound at $4.2bn (up 80%), prompting a raised outlook. Foundayo was approved and launched this month but isn’t included in the quarter’s figures. Shares rose about 9%, and Lilly faces competitive pressure from Novo Nordisk while Medicare deals helped push Zepbound prices down even as volumes grew; investors will watch for weekly prescription data and updates on Foundayo’s performance.

via Financial Times|
#business#eli-lilly#foundayo
Lilly’s Kelonia Buyout Tightens the In Vivo CAR-T M&A Frontier
business1 month ago

Lilly’s Kelonia Buyout Tightens the In Vivo CAR-T M&A Frontier

Eli Lilly agreed to pay up to $7 billion for Kelonia Therapeutics, marking another high-profile in vivo CAR-T deal as Big Pharma bets on the space; analysts say deal activity may slow due to a shrinking pool of viable targets, with Umoja Biopharma identified as a prime remaining buyout candidate and offshore players like Starna Therapeutics likely to surface. The pace will hinge on Kelonia’s data and whether the platform can extend beyond oncology into autoimmune indications.

via Fierce Biotech|
#biotech-manda#business#cell-therapy
Lilly Obesity Drugs Lag Wegovy in Early Prescription Data, Weighing on Stock
markets1 month ago

Lilly Obesity Drugs Lag Wegovy in Early Prescription Data, Weighing on Stock

Premarket, Eli Lilly shares fell after IQVIA data cited by Bloomberg showed Lilly’s obesity drugs Foundayo (oral) and Zepbound trailed Novo Nordisk’s Wegovy in weekly prescriptions; Zepbound fell about 2% week over week while Wegovy rose about 7% in the same period, and Foundayo posted 3,707 prescriptions in its first full week versus Wegovy’s roughly 18,410 in its first full week; analysts caution that one week of data isn’t definitive, but weak early momentum could pressure Lilly stock if the trend persists.

via Seeking Alpha|
#eli-lilly#foundayo#markets
Lilly strikes $3.25B buyout of Kelonia Therapeutics in high-stakes biotech bet
biotech1 month ago

Lilly strikes $3.25B buyout of Kelonia Therapeutics in high-stakes biotech bet

Eli Lilly agreed to acquire Kelonia Therapeutics for $3.25 billion, with potential additional payments tied to clinical, regulatory, and commercial milestones. Kelonia—formerly Elcano Therapeutics—had survived on about $60 million over five years and nearly ran out of cash on three occasions, aided by Venrock’s early backing. The deal highlights the volatile, milestone-driven journey of biotech startups and the race to capitalize on cell-therapy advances.

via statnews.com|
#acquisition#biotech#cell-therapies
business1 month ago

Lilly to Acquire Kelonia for Up to $7B to Advance In Vivo CAR-T Therapy

Eli Lilly agreed to acquire Kelonia Therapeutics for up to $7 billion, with $3.25 billion upfront and the rest tied to milestones, in a deal expected to close in the second half of 2026. Kelonia’s in vivo CAR-T technology aims to reprogram patients’ T-cells inside the body to attack cancer, potentially offering a one-time IV therapy compared with traditional ex vivo CAR-T. Lilly plans to apply the tech beyond multiple myeloma to other blood cancers and possibly solid tumors, as part of a broader push to diversify beyond obesity and diabetes drugs amid ongoing biotech dealmaking and competition from J&J and Gilead-backed therapies.

via CNBC|
#business#cancer-immunotherapy#eli-lilly
Amazon Pharmacy Lands Lilly’s Foundayo GLP-1 Pill for Same-Day Delivery
business1 month ago

Amazon Pharmacy Lands Lilly’s Foundayo GLP-1 Pill for Same-Day Delivery

Amazon Pharmacy will offer Eli Lilly’s new oral GLP-1 drug Foundayo with real-time availability and transparent pricing (insurance as low as $1/day or $25/mo; cash $5/day or $149/mo; automatic coupons), plus Same-Day Delivery nationwide and pharmacist-supported in-office kiosks at select One Medical locations, expanding access from about 3,000 to 4,500 cities by year-end; remote areas will have next-day to three-day delivery.

via Business Wire|
#amazon-pharmacy#business#eli-lilly
Lilly inks AI-driven oral drug deal with Insilico worth up to $2.75B
business1 month ago

Lilly inks AI-driven oral drug deal with Insilico worth up to $2.75B

Eli Lilly and Insilico Medicine have agreed to a commercialization deal valued at up to $2.75 billion (including $115 million upfront) to develop, manufacture, and bring to market Insilico’s AI-discovered preclinical oral drug candidates, with milestones tied to regulatory and commercial success. The companies deny rumors of a full acquisition, and specific asset details aren’t disclosed, though a GLP-1 candidate has been licensed to an undisclosed partner.

via statnews.com|
#ai-drug-discovery#biobucks#business